Skip to main content
SpringerLink
Log in

Cardiovascular Disease

  • Chapter
Biomarkers of Cardiometabolic Risk, Inflammation and Disease

  • 929 Accesses

Abstract

Inflammatory mechanisms play a major role in the pathogenesis of vascular and cardiac diseases. Several immune cells (including macrophages and T cells) participate in all stages of atherosclerosis, including initiation, progression, and plaque destabilization and rupture. Inflammation seems to play also a significant role in the beginning, maintenance, and perpetuation of atrial fibrillation (AF), the most common arrhythmia in clinical practice. It is not clear yet if inflammation occurs as a cause or a consequence of AF, but several inflammatory markers are elevated in AF and correlate to the outcomes of different rhythm control strategies and thrombogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.

    CAS  PubMed  Google Scholar 

  2. Skalén K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750–4.

    PubMed  Google Scholar 

  3. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969–79.

    CAS  PubMed  Google Scholar 

  4. Lip GYH, Beevers DG. ABC of atrial fibrillation: history, epidemiology, and importance of atrial fibrillation. BMJ. 1995;311(7016):1361–93.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Lloyd-Jones DM, Want TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–6.

    PubMed  Google Scholar 

  6. Pan M, Zhu JH, Jiang WP, Liu ZH, Li HM, Yu XH, et al. Inflammation: a possible pathogenic link to atrial fibrillation. Med Hypotheses. 2006;67(6):1305–7.

    PubMed  Google Scholar 

  7. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158(3):229–34.

    CAS  PubMed  Google Scholar 

  8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.

    CAS  PubMed  Google Scholar 

  9. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840–4.

    CAS  PubMed  Google Scholar 

  10. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.

    CAS  PubMed  Google Scholar 

  11. Patel AA, Ogden K, Veerman M, Mody SH, Nelson WW, Neil N. The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul Health Manag. 2014;17(3):159–65.

    PubMed Central  PubMed  Google Scholar 

  12. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6(2):187–200.

    PubMed Central  PubMed  Google Scholar 

  13. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15(2):152–8.

    CAS  PubMed  Google Scholar 

  14. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag. 2006;2(2):145–52.

    PubMed Central  PubMed  Google Scholar 

  15. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297–329.

    CAS  PubMed  Google Scholar 

  16. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28(11):1909–19.

    CAS  PubMed  Google Scholar 

  17. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007;7(6):467–77.

    CAS  PubMed  Google Scholar 

  18. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol. 1998;152(1):199–207.

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4):281–91.

    CAS  PubMed  Google Scholar 

  20. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38.

    CAS  PubMed  Google Scholar 

  21. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res. 2001;38:113–9.

    CAS  PubMed  Google Scholar 

  22. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009;7 Suppl 1:328–31.

    CAS  PubMed  Google Scholar 

  23. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–51.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost. 2011;105 Suppl 1:S34–42.

    CAS  PubMed  Google Scholar 

  25. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94(5):1931–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213–20.

    CAS  PubMed  Google Scholar 

  27. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408.

    CAS  PubMed  Google Scholar 

  28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–9.

    CAS  PubMed  Google Scholar 

  29. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.

    PubMed  Google Scholar 

  30. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–9.

    CAS  PubMed  Google Scholar 

  31. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

    CAS  PubMed  Google Scholar 

  32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–82.

    CAS  PubMed  Google Scholar 

  33. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol. 2005;46(7):1284–7.

    CAS  PubMed  Google Scholar 

  34. Wijffels M, Kirchhof C, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–68.

    CAS  PubMed  Google Scholar 

  35. Garrey WE. The nature of fibrillary contraction of the heart: its relation to tissue mass and form. Am J Physiol. 1964;33:397–414.

    Google Scholar 

  36. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66.

    PubMed  Google Scholar 

  37. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111(3):137–42.

    CAS  PubMed  Google Scholar 

  38. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180–4.

    CAS  PubMed  Google Scholar 

  39. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004;148(3):462–6.

    CAS  PubMed  Google Scholar 

  40. Toutouzas K, Synetos A, Drakopoulou M, Stefanadi E, Tousoulis D, Lerakis S, et al. The role of inflammation in atrial fibrillation: a myth or a fact? Am J Med Sci. 2009;338(6):494–9.

    PubMed  Google Scholar 

  41. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10.

    PubMed  Google Scholar 

  42. Chung M, Martin D, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886–91.

    CAS  PubMed  Google Scholar 

  43. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J. 2005;150(5):1064.

    PubMed  Google Scholar 

  44. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels. 2005;20(2):45–9.

    PubMed  Google Scholar 

  45. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol. 2005;98(1):73–7.

    PubMed  Google Scholar 

  46. Acevedo M, Corbalán R, Braun S, Pereira J, Navarrete C, Gonzalez I. C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol. 2006;108(3):326–31.

    PubMed  Google Scholar 

  47. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95(6):764–7.

    CAS  PubMed  Google Scholar 

  48. Aguiar FJ, Ferreira-Júnior M, Sales MM, Cruz-Neto LM, Fonseca LA, Sumita NM, et al. C-reactive protein: clinical applications and proposals for a rational use. Rev Assoc Med Bras. 2013;59(1):85–92.

    PubMed  Google Scholar 

  49. Hernández Madrid A. Proteína C reactiva y fibrilación auricular. Un viejo marcador en busca de un nuevo sitio. Rev Esp Cardiol. 2006;59:94–8.

    PubMed  Google Scholar 

  50. Li SB, Yang F, Jing L, Ma J, Jia YD, Dong SY, et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J Investig Med. 2013;61(4):722–7.

    CAS  PubMed  Google Scholar 

  51. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–8.

    CAS  PubMed  Google Scholar 

  52. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25(13):1100–7.

    CAS  PubMed  Google Scholar 

  53. Engelmann MDM, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26(20):2083–92.

    CAS  PubMed  Google Scholar 

  54. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010;31(14):1730–6.

    PubMed Central  PubMed  Google Scholar 

  55. Schairer DO, Levis WR. Atrial fibrillation: an inflammatory and autoimmune disorder. Heart Rhythm. 2012;9(2):e2.

    PubMed  Google Scholar 

  56. Fujiki A, Sakamoto T, Nishida K, Mizumaki K, Inoue H. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation. J Cardiovasc Pharmacol. 2007;50(3):264–6.

    CAS  PubMed  Google Scholar 

  57. Gungor B, Ekmekci A, Arman A, et al. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin Electrophysiol. 2013;36(10):1220–7.

    PubMed  Google Scholar 

  58. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21(9):1064–70.

    PubMed  Google Scholar 

  59. Deftereos S, Giannopoulos G, Kossyvakis C, Raisakis K, Angelidis C, Efremidis M, et al. Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence. Clin Biochem. 2013;46(12):1020–5.

    CAS  PubMed  Google Scholar 

  60. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the atherosclerosis risk in communities [ARIC] study). Am J Cardiol. 2012;109(1):95–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  61. Mira YE, Muhuyati, Lu WH, He PY, Liu ZQ, Yang YC. TGF-β1 signal pathway in the regulation of inflammation in patients with atrial fibrillation. Asian Pac J Trop Med. 2013;6(12):999–1003.

    CAS  PubMed  Google Scholar 

  62. Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, et al. Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. 2014;29(5):653–8.

    PubMed  Google Scholar 

  63. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. The role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438–44.

    PubMed Central  PubMed  Google Scholar 

  64. Kim Y, Guzik T, Zhang Y, Zhang MH, Kattach H, Ratnatunga C, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005;97(7):629–36.

    CAS  PubMed  Google Scholar 

  65. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38(4):1229–37.

    CAS  PubMed  Google Scholar 

  66. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346(8986):1313–4.

    CAS  PubMed  Google Scholar 

  67. Cianfrocca C, Loricchio ML, Pelliccia F, Pasceri V, Auriti A, Bianconi L, et al. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation. Int J Cardiol. 2010;142(1):22–8.

    PubMed  Google Scholar 

  68. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol. 2004;94(6):805–7.

    CAS  PubMed  Google Scholar 

  69. Thambidorai SK, Murray RD, Parakh K, Shah TK, Black IW, Jasper SE, et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol. 2005;96(78):935–41.

    PubMed  Google Scholar 

  70. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.

    CAS  PubMed  Google Scholar 

  71. Maehama T, Okura H, Imai K, Saito K, Yamada R, Koyama T, et al. Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation. J Cardiol. 2010;56(1):118–24.

    PubMed  Google Scholar 

  72. Providência R, Faustino A, Paiva L, Trigo J, Botelho A, Nascimento J, et al. Cardioversion safety in patients with nonvalvular atrial fibrillation: which patients can be spared transesophageal echocardiography? Blood Coagul Fibrinolysis. 2012;23(7):597–602.

    PubMed  Google Scholar 

  73. Maehama T, Okura H, Imai K, Yamada R, Obase K, Saito K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol. 2010;106(4):535–8.

    CAS  PubMed  Google Scholar 

  74. Aulin JK, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(14s1):E91.

    Google Scholar 

  75. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global utilization of streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol. 1997;30(2):406–13.

    CAS  PubMed  Google Scholar 

  76. Yoshizaki T, Umetani K, Ino Y, Takahashi S, Nakamura M, Seto T, et al. Activated inflammation is related to the incidence of atrial fibrillation in patients with acute myocardial infarction. Intern Med. 2012;51(12):1467–71.

    CAS  PubMed  Google Scholar 

  77. The Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.

    Google Scholar 

  78. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49(15):1642–8.

    CAS  PubMed  Google Scholar 

  79. Wu N, Xu B, Xiang Y, Wu L, Zhang Y, Ma X, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169(1):62–72.

    PubMed  Google Scholar 

  80. Lombardi F, Tundo F, Belletti S, Mantero A, Melzi D’eril GV. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. J Cardiovasc Med (Hagerstown). 2008;9(6):581–8.

    Google Scholar 

  81. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2007;99(10):1421–4.

    CAS  PubMed  Google Scholar 

  82. Celebi OO, Celebi S, Canbay A, Ergun G, Aydogdu S, Diker E. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion. Cardiology. 2011;118(3):168–74.

    CAS  PubMed  Google Scholar 

  83. Korantzopoulos P, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract. 2005;59(8):881–5.

    CAS  PubMed  Google Scholar 

  84. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol. 2006;97(9):1346–50.

    CAS  PubMed  Google Scholar 

  85. Cosgrave J, Foley JB, Bahadur K, Bennett K, Crean P, Walsh MJ. Inflammatory markers are not associated with outcomes following elective external cardioversion. Int J Cardiol. 2006;110(3):373–7.

    PubMed  Google Scholar 

  86. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.

    PubMed  Google Scholar 

  87. Kurotobi T, Iwakura K, Inoue K, Kimura R, Okamura A, Koyama Y, et al. A pre-existent elevated C-reactive protein is associated with the recurrence of atrial tachyarrhythmias after catheter ablation in patients with atrial fibrillation. Europace. 2010;12:1213–8.

    PubMed  Google Scholar 

  88. Liu J, Fang PH, Dibs S, Hou Y, Li XF, Zhang S. High-sensitivity C-reactive protein as a predictor of atrial fibrillation recurrence after primary circumferential pulmonary vein isolation. Pacing Clin Electrophysiol. 2011;34(4):398–406.

    PubMed  Google Scholar 

  89. Jiang Z, Dai L, Song Z, Li H, Shu M. Association between C-reactive protein and atrial fibrillation recurrence after catheter ablation: a meta-analysis. Clin Cardiol. 2013;36(9):548–54.

    PubMed  Google Scholar 

  90. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;20(21):2021–8.

    Google Scholar 

  91. Peña JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012;33(4):531–7.

    PubMed Central  PubMed  Google Scholar 

  92. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93(6):780–2.

    CAS  PubMed  Google Scholar 

  93. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004;62(1):105–11.

    CAS  PubMed  Google Scholar 

  94. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92(11):1343–5.

    CAS  PubMed  Google Scholar 

  95. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92(12):1379–83.

    CAS  PubMed  Google Scholar 

  96. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832–9.

    CAS  PubMed  Google Scholar 

  97. Pedersen O, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100(4):376–80.

    CAS  PubMed  Google Scholar 

  98. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548–57.

    CAS  PubMed  Google Scholar 

  99. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.

    CAS  PubMed  Google Scholar 

  100. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107(23):2926–31.

    PubMed  Google Scholar 

  101. Yang SS, Han W, Zhou HY, Dong G, Wang BC, Huo H, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl). 2008;121(1):38–42.

    CAS  Google Scholar 

  102. Brinkley DM, Chen J. Effect of spironolactone on atrial fibrillation in patients with heart failure. Heart Rhythm. 2010;7:S262.

    Google Scholar 

  103. Marcus GM, Hsu JC. Colchicine after pulmonary vein isolation to prevent the early recurrence of atrial fibrillation, mollifying an inflammatory response? J Am Coll Cardiol. 2012;60(18):1797–8.

    CAS  PubMed  Google Scholar 

  104. January CT, Wann LS, Alpert JS, Calkins H, Cleveland Jr JC, Cigarroa JE, et al. Practice Guidelines and the Heart Rhythm Society Report of the American College of Cardiology/American Heart Association Task Force on 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation. 2014;2014(3):735–1097.

    Google Scholar 

Download references

Acknowledgments/Support

The authors thank Portuguese Foundation for Science and Technology (FCT), COMPETE-FEDER and POPH/FSE, through the following support: PTDC/SAU-TOX/114253/2009 and UID/NEU/04539/2013 (CNC.IBILI).

Author information

Authors and Affiliations

  1. Department of Cardiology – B, Centro Hospitalar e Universitário de Coimbra, Quinta dos Vales, S. Martinho do Bispo, Coimbra, 3041-801, Portugal

    Andreia Fernandes M.D., Rui Providência M.D., M.Sc. & Lino Gonçalves M.D., Ph.D.

  2. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), and CNC.IBILI Research Unit, Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Flávio Reis Ph.D.

Authors
  1. Andreia Fernandes M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rui Providência M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flávio Reis Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lino Gonçalves M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lino Gonçalves M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Filipe Palavra

  2. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Flávio Reis

  3. Department of Internal Medicine – B, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    Daniela Marado

  4. Interdisciplinary Centre of Research Egas Moniz, CiiEM, Caparica, Portugal

    Armando Sena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fernandes, A., Providência, R., Reis, F., Gonçalves, L. (2015). Cardiovascular Disease. In: Palavra, F., Reis, F., Marado, D., Sena, A. (eds) Biomarkers of Cardiometabolic Risk, Inflammation and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-16018-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16018-4_2

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16017-7

  • Online ISBN: 978-3-319-16018-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation